|
Headline: A prescription that may weaken the patient Source: Euromoney Date: April 2000 Author: Mark Kessel After a year-long campaign against accounting abuses that inflate earnings, the US Securities & Exchange Commission (SEC) has issued its long-awaited directives concerning these “earnings management” practices. Companies may now feel these decrees provide them with guidelines to avoid the kind of SEC prosecutions that have earned brand-name companies unwanted publicity – not to mention attacks from the plaintiff bar. |
Access intelligence that drives action
To unlock this research, enter your email to log in or enquire about access
